New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies
In this paper we report the synthesis of new A1/A3 adenosine receptor antagonists designed as simplification products of the A1 antagonists with pyrazolo[1′,5′:1,6]pyrimido [4,5-d]pyridazin-4(3H)-one scaffold previously developed by us. Notably, selective A1R antagonists are promising therapeutic ag...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | European Journal of Medicinal Chemistry Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772417425000093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850026410756800512 |
|---|---|
| author | Letizia Crocetti Abigail Pearce Venkat S. Vege Qi Xu Jing Xu Hannes Buthmann Maria Paola Giovannoni Gabriella Guerrini Francesca Catarzi Silvia Selleri Xianglin Huang Aneesh Chandran Graham Ladds Agostino Cilibrizzi |
| author_facet | Letizia Crocetti Abigail Pearce Venkat S. Vege Qi Xu Jing Xu Hannes Buthmann Maria Paola Giovannoni Gabriella Guerrini Francesca Catarzi Silvia Selleri Xianglin Huang Aneesh Chandran Graham Ladds Agostino Cilibrizzi |
| author_sort | Letizia Crocetti |
| collection | DOAJ |
| description | In this paper we report the synthesis of new A1/A3 adenosine receptor antagonists designed as simplification products of the A1 antagonists with pyrazolo[1′,5′:1,6]pyrimido [4,5-d]pyridazin-4(3H)-one scaffold previously developed by us. Notably, selective A1R antagonists are promising therapeutic agents in Alzheimer's disease and for the treatment of cognitive deficits, while A3R antagonists are potentially useful in the treatment of ischemia and certain types of cancer. Initial screening with NanoBRET competition binding assay revealed a number of products with pKi ≥5 for A1R and A3R. For some representative compounds the antagonist profiles, as well as their selectivity versus A2AR and A2BR, have been also validated by antagonizing NECA in cAMP accumulation. The most interesting compounds resulted the A1/A3 mixed antagonist 3b (pKi = 6.41 and 6.29 for A1R and A3R respectively, pKb = 5.00 and 5.27 for the A2aR and A2bR) and the selective A3R antagonist 5c (pKi = 6.40, pKb values of 4.44, 6.17, 4.16, and 4.78 for the A1R, A3R, A2aR and A2bR, respectively). Furthermore, in silico simulations were carried out to study the molecular mechanism of the high affinity of 3b for A1/A3Rs as well as the selectivity of 5c for A3R over A1R. Overall, this work highlights new series of bicyclic small-molecules as valid candidates for further structural optimization towards the development of therapeutically relevant A1/A3 adenosine receptor antagonists. |
| format | Article |
| id | doaj-art-9d7d33e1486c461584bca66885fcc7d3 |
| institution | DOAJ |
| issn | 2772-4174 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Journal of Medicinal Chemistry Reports |
| spelling | doaj-art-9d7d33e1486c461584bca66885fcc7d32025-08-20T03:00:32ZengElsevierEuropean Journal of Medicinal Chemistry Reports2772-41742025-04-011310025310.1016/j.ejmcr.2025.100253New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategiesLetizia Crocetti0Abigail Pearce1Venkat S. Vege2Qi Xu3Jing Xu4Hannes Buthmann5Maria Paola Giovannoni6Gabriella Guerrini7Francesca Catarzi8Silvia Selleri9Xianglin Huang10Aneesh Chandran11Graham Ladds12Agostino Cilibrizzi13NEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy; Corresponding author.Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UKDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UKInstitute of Pharmaceutical Science, King's College London, Stamford Street, London, SE1 9NH, UKInstitute of Pharmaceutical Science, King's College London, Stamford Street, London, SE1 9NH, UKDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UKNEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, ItalyNEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, ItalyNEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, ItalyNEUROFARBA, Pharmaceutical and Nutraceutical Section, University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, ItalyDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UKDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK; Department of Biotechnology & Microbiology, Kannur University, Kannur, 670 661, Kerala, IndiaDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK; Corresponding author.Institute of Pharmaceutical Science, King's College London, Stamford Street, London, SE1 9NH, UK; Corresponding author.In this paper we report the synthesis of new A1/A3 adenosine receptor antagonists designed as simplification products of the A1 antagonists with pyrazolo[1′,5′:1,6]pyrimido [4,5-d]pyridazin-4(3H)-one scaffold previously developed by us. Notably, selective A1R antagonists are promising therapeutic agents in Alzheimer's disease and for the treatment of cognitive deficits, while A3R antagonists are potentially useful in the treatment of ischemia and certain types of cancer. Initial screening with NanoBRET competition binding assay revealed a number of products with pKi ≥5 for A1R and A3R. For some representative compounds the antagonist profiles, as well as their selectivity versus A2AR and A2BR, have been also validated by antagonizing NECA in cAMP accumulation. The most interesting compounds resulted the A1/A3 mixed antagonist 3b (pKi = 6.41 and 6.29 for A1R and A3R respectively, pKb = 5.00 and 5.27 for the A2aR and A2bR) and the selective A3R antagonist 5c (pKi = 6.40, pKb values of 4.44, 6.17, 4.16, and 4.78 for the A1R, A3R, A2aR and A2bR, respectively). Furthermore, in silico simulations were carried out to study the molecular mechanism of the high affinity of 3b for A1/A3Rs as well as the selectivity of 5c for A3R over A1R. Overall, this work highlights new series of bicyclic small-molecules as valid candidates for further structural optimization towards the development of therapeutically relevant A1/A3 adenosine receptor antagonists.http://www.sciencedirect.com/science/article/pii/S2772417425000093G protein-coupled receptorAdenosine receptorAntagonistBRETBindingcAMP |
| spellingShingle | Letizia Crocetti Abigail Pearce Venkat S. Vege Qi Xu Jing Xu Hannes Buthmann Maria Paola Giovannoni Gabriella Guerrini Francesca Catarzi Silvia Selleri Xianglin Huang Aneesh Chandran Graham Ladds Agostino Cilibrizzi New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies European Journal of Medicinal Chemistry Reports G protein-coupled receptor Adenosine receptor Antagonist BRET Binding cAMP |
| title | New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies |
| title_full | New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies |
| title_fullStr | New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies |
| title_full_unstemmed | New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies |
| title_short | New heterocyclic A1/A3 adenosine receptor ligands through molecular simplification strategies |
| title_sort | new heterocyclic a1 a3 adenosine receptor ligands through molecular simplification strategies |
| topic | G protein-coupled receptor Adenosine receptor Antagonist BRET Binding cAMP |
| url | http://www.sciencedirect.com/science/article/pii/S2772417425000093 |
| work_keys_str_mv | AT letiziacrocetti newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT abigailpearce newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT venkatsvege newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT qixu newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT jingxu newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT hannesbuthmann newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT mariapaolagiovannoni newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT gabriellaguerrini newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT francescacatarzi newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT silviaselleri newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT xianglinhuang newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT aneeshchandran newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT grahamladds newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies AT agostinocilibrizzi newheterocyclica1a3adenosinereceptorligandsthroughmolecularsimplificationstrategies |